Patents by Inventor Steven C. BORKAN

Steven C. BORKAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND/OR TREATING KIDNEY INJURY
    Publication number: 20240376166
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Application
    Filed: May 10, 2024
    Publication date: November 14, 2024
    Applicant: Boston Medical Center Corporation
    Inventors: Steven C. BORKAN, Zhiyong WANG
  • POLYPEPTIDE BAX/NPM INHIBITORS
    Publication number: 20240309060
    Abstract: Described herein are polypeptides comprising at least one nucleophosmin-binding domain, including engineered polypeptides, and methods of using such polypeptides to treat or prevent acute kidney injury and/or kidney ischemia.
    Type: Application
    Filed: March 15, 2024
    Publication date: September 19, 2024
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Steven C. Borkan, Aaron B. Beeler, Zhiyong Wang, Jac Lorenzo, Karen N. Allen
  • Compositions and methods for diagnosing and/or treating kidney injury
    Patent number: 12018058
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: June 25, 2024
    Assignee: Boston Medical Center Corporation
    Inventors: Steven C. Borkan, Zhiyong Wang
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND/OR TREATING KIDNEY INJURY
    Publication number: 20210403521
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 30, 2021
    Applicant: Boston Medical Center Corporation
    Inventors: Steven C. BORKAN, Zhiyong WANG
  • Compositions and methods for diagnosing and/or treating kidney injury
    Patent number: 11136363
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: October 5, 2021
    Assignee: Boston Medical Center Corporation
    Inventors: Steven C. Borkan, Zhiyong Wang
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND/OR TREATING KIDNEY INJURY
    Publication number: 20190256567
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Application
    Filed: February 1, 2019
    Publication date: August 22, 2019
    Applicant: Boston Medical Center Corporation
    Inventors: Steven C. BORKAN, Zhiyong WANG